# Efficacy and Safety of SOX Regimen Combined With Camrelizumab as Neoadjuvant Treatment in Locally Advanced Gastric Cancer: a Phase II, Single-arm Study

> **NCT05602935** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **The Second Affiliated Hospital of Fujian Medical University** · enrollment: 29 (estimated)

## Conditions studied

- Stomach Neoplasms
- Digestive System Neoplasms
- Neoplasms
- Digestive System Diseases
- Stomach Diseases
- Neoplasms by Site

## Interventions

- **DRUG:** Camrelizumab
- **DRUG:** SOX
- **PROCEDURE:** Surgery

## Key facts

- **NCT ID:** NCT05602935
- **Lead sponsor:** The Second Affiliated Hospital of Fujian Medical University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2020-09-16
- **Primary completion:** 2022-03-30
- **Final completion:** 2026-12-30
- **Target enrollment:** 29 (ESTIMATED)
- **Last updated:** 2023-09-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05602935

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05602935, "Efficacy and Safety of SOX Regimen Combined With Camrelizumab as Neoadjuvant Treatment in Locally Advanced Gastric Cancer: a Phase II, Single-arm Study". Retrieved via AI Analytics 2026-07-09 from https://api.ai-analytics.org/clinical/NCT05602935. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*